TELA Bio Q1 revenue $19.1M (+3% YoY); net loss $12.3M; reiterates FY2026 revenue growth at least 8%

TELA Bio, Inc.

Revenue $19.1M (+3% YoY), unit growth 13%; European revenue up 41% YoY.
Net loss $12.3M vs $11.3M prior year; operating loss $10.5M.
Gross margin 65.7% (down from 67.6%) on higher excess/obsolete inventory charge.
Reiterated FY2026 revenue growth at least 8% over FY2025; Q2 2026 expected ~$20.0M.
U.S. commercial launch of OviTex LTR (April 1) and board refreshment effective June 9, 2026.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

TELA Bio, Inc. reported first quarter ended March 31, 2026 results: revenue $19.1 million, net income Net loss was $12.3 million. Guidance reaffirmed.

Period: first quarter ended March 31, 2026
Revenue: $19.1 million
Net income: Net loss was $12.3 million
Guidance: reaffirmed
Result: reported results

Exact text from the filing

at the conclusion of the 2026 Annual Meeting on June 9, 2026; · Noted the U.S. commercial organization is fully staffed at planned 2026 levels; · Delivered revenue of $19.1 million in the first quarter of 2026, representing growth of 3% over the prior year period; · Accelerated European revenue growth to 41% over the prior year period, with continued

View on SEC.gov

49 earnings releases filed in the last 30 days. Browse all earnings releases →

TELA Bio, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-26-059393

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.